SMN2 and Duchenne muscular dystrophy: So far this kind of splice‐switching AON has been approved by FDA for several diseases, including Eteplirsen (2016) and Golodirsen (2019) for Duchenne muscular dystrophy (DMD), and Nusinersen (2016) for spinal muscular atrophy (SMN2).